CA2530529A1 - Compositions and methods for selective dissolution of nascent intravascular blood clots - Google Patents

Compositions and methods for selective dissolution of nascent intravascular blood clots Download PDF

Info

Publication number
CA2530529A1
CA2530529A1 CA002530529A CA2530529A CA2530529A1 CA 2530529 A1 CA2530529 A1 CA 2530529A1 CA 002530529 A CA002530529 A CA 002530529A CA 2530529 A CA2530529 A CA 2530529A CA 2530529 A1 CA2530529 A1 CA 2530529A1
Authority
CA
Canada
Prior art keywords
rbc
tpa
clots
blood
supar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002530529A
Other languages
English (en)
French (fr)
Inventor
Vladimir R. Muzykantov
Juan Carlos Murciano
Douglas Cines
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2530529A1 publication Critical patent/CA2530529A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA002530529A 2003-07-01 2004-06-28 Compositions and methods for selective dissolution of nascent intravascular blood clots Abandoned CA2530529A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/611,723 2003-07-01
US10/611,723 US7041287B2 (en) 1998-05-21 2003-07-01 Compositions and methods for selective dissolution of nascent intravascular blood clots
PCT/US2004/020660 WO2005004804A2 (en) 2003-07-01 2004-06-28 Compositions and methods for selective dissolution of nascent intravascular blood clots

Publications (1)

Publication Number Publication Date
CA2530529A1 true CA2530529A1 (en) 2005-01-20

Family

ID=34062346

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002530529A Abandoned CA2530529A1 (en) 2003-07-01 2004-06-28 Compositions and methods for selective dissolution of nascent intravascular blood clots

Country Status (6)

Country Link
US (2) US7041287B2 (enExample)
EP (1) EP1648497A2 (enExample)
JP (1) JP2007521294A (enExample)
AU (1) AU2004255196B2 (enExample)
CA (1) CA2530529A1 (enExample)
WO (1) WO2005004804A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1093378A4 (en) * 1998-05-21 2001-10-10 Univ Pennsylvania COMPOSITIONS AND TECHNIQUES FOR PREVENTING AND TREATING ANARCHIC FORMATION OF INTRAVASCULAR FIBRINOUS CLOTS
US7674466B2 (en) * 1999-08-05 2010-03-09 The Trustees Of The University Of Pennsylvania Targeting and prolonging association of drugs to the luminal surface of the pulmonary vascular endothelial cells using antibodies that bind to ICAM-1
US7405276B2 (en) * 2000-11-01 2008-07-29 Elusys Therapeutics, Inc. Method of producing bispecific molecules by protein trans-splicing
US20070003552A1 (en) * 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
EP1380290A1 (en) * 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-beta structure pathway and its therapeutic relevance
US20080317761A1 (en) * 2004-04-28 2008-12-25 The Trustees Of The University Of Pennsylvania Peptide-Mediated Protein Transduction Into Cells of the Hematopoietic Lineage
EP1814914A2 (en) * 2004-10-29 2007-08-08 The Regents of the University of Colorado Antibodies that bind urokinase-type plasminogen activator and epitopes therefor
US20090202980A1 (en) * 2005-03-21 2009-08-13 Crossbeta Biosciences B.V. Cross-Beta Structure Comprising Amyloid Binding Proteins and Methods for Detection of the Cross-Beta Structure, for Modulating Cross-Beta Structures Fibril Formation and for Modulating Cross-Beta Structure-Mediated Toxicity and Method for Interfering With Blood Coagulation
US8114832B2 (en) * 2005-07-13 2012-02-14 Crossbeta Biosciences B.V. Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
WO2007008072A2 (en) * 2005-07-13 2007-01-18 Crossbeta Biosciences B.V. CROSS-ß STRUCTURE BINDING COMPOUNDS
EP1907864A2 (en) * 2005-07-13 2008-04-09 Crossbeta Biosciences B.V. METHODS FOR DETERMINING THE EFFECT OF A TREATMENT ON THE CROSS-ß STRUCTURE CONTENT OF A PROTEIN; SELECTION OF TREATMENTS AND USES THEREOF
WO2008039206A2 (en) * 2005-10-05 2008-04-03 The Trustees Of The University Of Pennsylvania Fusion proteins for inhibition and dissolution of coagulation
US20100015126A1 (en) * 2006-03-17 2010-01-21 Martijn Frans Ben Gerard Gebbink Methods of Binding of Cross-Beta Structures By Chaperones
WO2008147526A1 (en) * 2007-05-23 2008-12-04 The Trustees Of The University Of Pennsylvania Targeted carriers for intracellular drug delivery
EP2058001A1 (en) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Enhancement of immunogenicity of antigens
EP2058000A1 (en) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Immunogenic compositions capable of activating T cells
US8333973B2 (en) * 2008-01-02 2012-12-18 The Trustees Of The University Of Pennsylvania Targeting recombinant therapeutics to circulating red blood cells
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
CA2807942C (en) 2010-08-10 2021-07-27 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
EP2976109B1 (en) 2013-03-21 2018-07-25 Genisphere, LLC Cellular delivery of dna intercalating agents
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10821157B2 (en) 2014-02-21 2020-11-03 Anokion Sa Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
WO2017143156A1 (en) 2016-02-19 2017-08-24 Genisphere Llc Nucleic acid carriers and therapeutic methods of use
EP3638296A1 (en) 2017-06-16 2020-04-22 The University Of Chicago Compositions and methods for inducing immune tolerance
EA202092723A1 (ru) 2018-05-09 2021-04-09 Зе Юниверсити Оф Чикаго Композиции и способы, касающиеся иммунной толерантности

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60200169A (ja) * 1984-03-23 1985-10-09 Green Cross Corp:The 線維素溶解酵素前駆体測定用試薬
EP1093378A4 (en) * 1998-05-21 2001-10-10 Univ Pennsylvania COMPOSITIONS AND TECHNIQUES FOR PREVENTING AND TREATING ANARCHIC FORMATION OF INTRAVASCULAR FIBRINOUS CLOTS

Also Published As

Publication number Publication date
AU2004255196A1 (en) 2005-01-20
US20060140917A1 (en) 2006-06-29
AU2004255196B2 (en) 2009-10-08
JP2007521294A (ja) 2007-08-02
WO2005004804A3 (en) 2005-05-12
US20040053408A1 (en) 2004-03-18
US7041287B2 (en) 2006-05-09
WO2005004804A2 (en) 2005-01-20
EP1648497A2 (en) 2006-04-26

Similar Documents

Publication Publication Date Title
AU2004255196B2 (en) Compositions and methods for selective dissolution of nascent intravascular blood clots
US6488927B2 (en) Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots
US11124787B2 (en) ADAMTS13-containing compositions having thrombolytic activity
AU599392B2 (en) Fibrinolytic composition
CA1281647C (en) Compositions and methods for the treatment of bleeding disorders
Absar et al. Engineering of plasminogen activators for targeting to thrombus and heightening thrombolytic efficacy
WO1998058661A1 (en) Use of fviia for the treatment of bleedings in patients with a normal blood clotting cascade and normal platelet function
Murciano et al. Soluble urokinase receptor conjugated to carrier red blood cells binds latent pro-urokinase and alters its functional profile
Mellott et al. Acceleration of recombinant tissue-type plasminogen activator-induced reperfusion and prevention of reocclusion by recombinant antistasin, a selective factor Xa inhibitor, in a canine model of femoral arterial thrombosis.
JPH03504717A (ja) 血餅溶解の促進のための組成物及び方法
JPH049334A (ja) 線溶活性増強剤
Kashyap et al. Principles of thrombolysis
Durocher et al. Thrombolysis in Stroke
WO2018089248A2 (en) E-we thrombin analog and fibrinolytic combination

Legal Events

Date Code Title Description
FZDE Dead